Patient Demographics and Baseline Disease Characteristics, Motesanib Exposure (Phase 2 Study).
收藏Figshare2015-12-02 更新2026-04-29 收录
下载链接：
https://figshare.com/articles/dataset/_Patient_Demographics_and_Baseline_Disease_Characteristics_Motesanib_Exposure_Phase_2_Study_/1204370
下载链接
链接失效反馈官方服务：
资源简介：
C1h = plasma motesanib concentration at 1 hour; C24h = plasma motesanib concentration at 24 hours; ECOG = Eastern Cooperative Oncology Group; IQR = interquartile range; PLGF = placental growth factor; QD = once daily.*Includes Hispanic, American Indian or Alaska Native, and other.†As assessed by investigator.‡Includes all cancer therapies before study enrollment.§Only 22 of 24 patients in the “undetermined” group received motesanib and were therefore evaluated for motesanib exposure. Motesanib concentrations in plasma were determined using a validated liquid chromatography/tandem mass spectrometry method (Cedra Corp., Austin, TX).Patient Demographics and Baseline Disease Characteristics, Motesanib Exposure (Phase 2 Study).
创建时间：
2015-12-02
